Hikma revenue growth reached 7% in 2025, as the company reported total revenue of $3.349 billion for the year ended December 31, 2025. This figure compares to $3.127 billion in 2024. The company achieved increases across North America, MENA, and Europe.
Hikma Revenue Growth by Business Segments
The Injectables business recorded core revenue of $1,423 million, up 7% from $1,324 million in 2024. North America sales rose 5%, while Europe and Rest of World grew 23%. MENA Injectables sales increased 9%.
Branded business revenue climbed 10% to $849 million from $769 million. Moreover, Hikma Rx revenue stood at $1,037 million, up from $1,026 million. The company launched 84 products across markets in 2025.
In the US, Hikma introduced Tyzavan®, a room temperature stable vancomycin bag, and its first biosimilar, ustekinumab. In Europe, Injectables saw double-digit growth. In MENA, palbociclib and dapagliflozin tablets expanded oncology and diabetes offerings.
“Strong momentum in our Branded and Hikma Rx businesses and growth in all our geographies enabled us to deliver Group revenue and profit growth in line with guidance and resilient margins.”
Said Darwazah, Chief Executive Officer, Hikma Pharmaceuticals
Share Buyback Programme
Hikma announced a $250 million share buyback programme for 2026. The Board cited strong cash generation and balance sheet strength. Furthermore, the company increased its total dividend by 5%.
The programme maintains balance sheet efficiency. It also provides headroom for investments. Economy analysts note such moves signal confidence in future prospects.
Leadership and Board Changes
Said Darwazah steps down as Executive Chairman to focus on CEO duties for two years. Victoria Hull, former Senior Independent Director, becomes Chair. Douglas Hurt assumes the Senior Independent Director role.
Mazen Darwazah takes Deputy CEO, MENA role. Khalid Nabilsi becomes Deputy CEO, North America and Europe, leaving CFO position. Areb Kurdi serves as Acting CFO during the search. All changes take effect immediately.
Hafrun Fridriksdottir becomes President, US, overseeing Injectables sales there. The shifts aim to enhance strategy execution. In MENA, Hikma became the largest pharmaceutical company by sales in 2025, up from second in 2024.
Market Positions and Outlook
Hikma ranks seventh among US generic medicine suppliers and third in generic injectables by volume. In Europe, it holds positions in critical medicines. The company signed 14 MENA deals in 2025, totaling 43 since 2023 with 29 partners.
Partnership with Celltrion expanded to six biosimilars in MENA. Health-tech advancements include 118 pipeline products, with 50 Injectables launches globally. Outlook projects Group revenue growth of 2% to 4%, Injectables in low single digits, Branded 6% to 8%, and Hikma Rx flat.
Investments target Injectables capabilities in sales, manufacturing, and R&D. Meanwhile, Branded focuses on oncology and chronic treatments like Finjuve in Saudi Arabia. These steps support sustainable growth amid regional demands.
